The Psychiatric Pipeline in Review: Quarter 2, 2025
Psychiatric Times
JULY 7, 2025
MindMed initiated a phase 3 study of MM120 for major depressive disorder, with results expected in the second half of 2026. Cybin partnered with Osmind to advance psychiatry programs, focusing on CYB003 and CYB004 for major depressive and generalized anxiety disorders.
Let's personalize your content